menu
    • menu

    Company profile for Lumosa Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. his model is executed by a highly capable and experienced cross-functional teams o...
    Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and inflammatory diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. his model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lumosa TherapeuticsTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    4th Floor, No. 3-2, Park Street, Nangang District, Taipei, 11503
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lumosa.com.tw/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sunten-phytotech-co--ltd-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/LumosaTherapeu1

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lumosa Therapeutics Reports Positive Phase 2b Trial Results
    Lumosa Therapeutics Reports Positive Phase 2b Trial Results

    28 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lumosa-therapeutics-announces-positive-results-from-lt3001intravenous-odatroltide-phase-2b-clinical-trial-in-acute-ischemic-stroke-302596427.html

    PR NEWSWIRE
    28 Oct 2025
    Share Share
    Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
    Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

    02 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lumosa-therapeutics-and-chi-memorial-announce-new-study-for-acute-stroke-302052041.html

    PR NEWSWIRE
    02 Feb 2024
    Share Share
    Lumosa's stroke drug lowers risk of deadly complication
    Lumosa's stroke drug lowers risk of deadly complication

    04 Aug 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/lumosa-posts-positive-safety-neurological-improvement-results-for-midstage-stroke-drug

    Kyle LaHucik FIERCEBIOTECH
    04 Aug 2021
    Share Share
    LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection
    LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection

    22 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lt1001-naldebainr-an-extended-release-analgesic-injection-received-its-second-approval-from-singapores-hsa-301196794.html

    PRNEWSWIRE
    22 Dec 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search